,i #aaith ,,congress #b;d ,session ,h4 ,r4 #ieei ,,in ,,the ,,house ,,of ,,representatives ,june #cj1 #bjbf,mr4 ,luttrell 7for himself1 ,mr4 ,mc,caul1 ,mr4 ,bergman1 and ,mr4 ,correa7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committees on the ,judiciary1 and ,veterans' ,affairs1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to accelerate the development of1 and access to1 psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the ,united ,states1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,initiating ,biomedical ,outcomes to ,garner ,advancements into ,innovative ,neuroplastogen ,efficacy ,act or the ,,ibogaine ,act4 #b4 ,table of contents ,the table of contents of this ,act is as follows3 ,sec4 #a4 ,short title4 ,sec4 #b4 ,table of contents4 ,sec4 #c4 ,definitions4 ,sec4 #d4 ,national ,health ,priority ,voucher ,pilot ,program4 ,sec4 #e4 ,amendment to the ,federal right to try law4 ,sec4 #f4 ,special registration requirements related to right to try4 ,sec4 #g4 ,revising considerations for ,,dea quota requirements4 ,sec4 #h4 ,federal-,state collaboration4 ,sec4 #i4 ,interagency collaboration with the private sector4 ,sec4 #aj4 ,timely rescheduling4 ,sec4 #aa4 ,designation of senior official for emerging therapeutic interventions within the ,department of ,veterans ,affairs4 ,sec4 #ab4 ,emerging therapeutic interventions at the ,department of ,veterans ,affairs4 ,sec4 #ac4 ,report on accelerating medical treatments for serious mental illness4 #c4 ,definitions ,section #ajb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hjb7 is amended by adding at the end the following3 7#fa7 ,the term ibogaine means-- 7,a7 all parts of the plant ,tabernanthe iboga2 and 7,b7 any similar compound or analog that-- 7i7 acts on neuroplasticity1 opioid receptors1 or serotonergic pathways that-- 7,i7 interrupt addiction cycles2 and 7,,ii7 restore neurological function disrupted by trauma1 chronic substance use1 or traumatic brain injury2 and 7ii7 are distinct in mechanism from the breakthrough therapies designated under section #ejf of the ,federal ,food1 ,drug1 and ,cosmetic ,act4 4 #d4 ,national ,health ,priority ,voucher ,pilot ,program ,subchapter ,a of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cea et seq47 is amended by adding at the end the following3 #ebd;,c4 ,national ,health ,priority ,voucher ,pilot ,program 7a7 ,definitions ,in this section3 7#a7 ,priority review ,the term priority review1 with respect to a human drug application as defined in section #gce7a71 means review and action by the ,secretary on such application not later than #f months after receipt by the ,secretary of such application1 as described in the ,manual of ,policies and ,procedures of the ,food and ,drug ,administration and goals identified in the letters described in section #aja7;c7 of the ,food and ,drug ,administration ,amendments ,act of #bjjg4 7#b7 ,national health priority review voucher ,the term national health priority review voucher means a voucher issued by the ,secretary to the sponsor of a national health priority product application that entitles the holder of such voucher to priority review of a single human drug application submitted under section #eje7;b77#a7 of this ,act or section #cea of the ,public ,health ,service ,act after the date of approval of the national health priority product application4 7#c7 ,national health priority product ,the term national health priority product means any of the following3 7,a7 ,public health crisis response ,a product to treat or prevent an urgent or emerging threat that the ,secretary has identified as having a significant impact on the population of the ,united ,states4 7,b7 ,breakthrough therapies ,a drug that-- 7i7 is designated as a breakthrough therapy under section #ejf7;a72 and 7ii7 is a transformative treatment with one or more novel mechanisms that fundamentally change the management of one or more diseases or conditions4 7,c7 ,large unmet medical needs ,a therapy for a disease or condition for which existing treatments inadequately address patient outcomes4 7,d7 ,onshoring and supply chain resilience ,a product whose development or manufacture in the ,united ,states would strengthen the ,nation's domestic capacity1 reduce foreign dependency1 and improve national security with respect to the drug supply chain4 7,e7 ,affordability ,a product that-- 7i7 improves overall value through reduced costs to the health care system2 or 7ii7 enhances access to important health care products4 7,f7 ,other products ,any other national health priority product whose approval would-- 7i7 address a health crisis in the ,united ,states2 7ii7 deliver an innovative cure2 7iii7 address an unmet public health need2 and 7iv7 increase domestic drug manufacturing as a matter of national security4 7#d7 ,national health priority product application ,the term national health priority product application means an application that-- 7,a7 is a human drug application as defined in section #gce7a72 and 7,b7 is for a national health priority product4 7b7 ,priority review voucher 7#a7 ,in general ,the ,secretary shall award a national health priority review voucher to the sponsor of a national health priority product application upon approval by the ,secretary of such application4 7#b7 ,prohibition on transferability ,the sponsor of a national health priority product that receives a national health priority review voucher may not transfer the entitlement to such voucher1 except that if ownership of the sponsor is transferred to a different entity the entitlement to such voucher may be transferred to such entity as part of the change in ownership4 7#c7 ,limitations ,a sponsor of a national health priority product application may not-- 7,a7 receive more than one national health priority review voucher during any #bd-month period2 or 7,b7 apply for an additional national health priority review voucher while in possession of such a voucher4 7c7 ,priority voucher user fee 7#a7 ,in general ,the ,secretary may establish a user fee program under which a sponsor of a human drug application that is the subject of a national health priority review voucher shall pay to the ,secretary a fee determined under paragraph 7#b74 ,such fee shall be in addition to any fee required to be submitted by the sponsor under chapter ,,vii4 7#b7 ,fee amount ,the amount of the user fee under paragraph 7#a7 shall be determined each fiscal year by the ,secretary and based on the average cost incurred by the agency in the review of a human drug application subject to priority review in the previous fiscal year4 7#c7 ,annual fee setting ,the ,secretary shall establish1 before the beginning of each fiscal year beginning after ,september #cj1 #bjbf1 for that fiscal year1 the amount of the user fee under paragraph 7#a74 7#d7 ,offsetting collections ,fees collected pursuant to this subsection for any fiscal year-- 7,a7 shall be deposited and credited as offsetting collections to the account providing appropriations to the ,food and ,drug ,administration2 and 7,b7 shall not be collected for any fiscal year except to the extent provided in advance in appropriation ,acts4 7d7 ,eligibility for other programs ,nothing in this section precludes a sponsor who seeks a national health priority review voucher from participating in any other incentive program1 including under this ,act1 except that no sponsor of a national priority health product application may receive more than one national health priority review voucher with respect to the drug for which the application is made4 7e7 ,relation to other provisions ,the provisions of this section shall supplement1 not supplant1 any other provisions of this ,act or the ,public ,health ,service ,act that encourage the development of drugs for tropical diseases1 rare pediatric diseases1 or national health priority products4 7f7 ,advice ,the ,secretary shall provide prompt advice to the sponsor of a national health priority product application for which the sponsor seeks a voucher under this section to enable the sponsor-- 7#a7 to plan a development program to obtain the necessary data for approval of the national health priority product that is the subject of such application2 and 7#b7 to conduct any additional studies that would be required for approval of such product for use in a broader population4 7g7 ,,gao study and report 7#a7 ,study 7,a7 ,in general ,the ,comptroller ,general of the ,united ,states shall conduct a study of the effectiveness of awarding national health priority review vouchers in the development of human drug products4 7,b7 ,contents of study ,in conducting the study under subparagraph 7,a71 the ,comptroller ,general shall examine the following3 7i7 ,with respect to each national health priority review voucher awarded3 7,i7 ,whether1 and to what extent1 an unmet need related to the treatment or prevention of a disease or condition was met through the approval of a national health priority product4 7,,ii7 ,identification of each drug for which the voucher was used4 7,,iii7 ,the length of the period of time between the date on which the voucher was awarded and the date on which it was used4 7ii7 ,whether the pathway under this section has helped to provide safe and effective treatments for patients4 7iii7 ,whether a similar voucher program would be appropriate for other categories of drugs4 7#b7 ,report ,not later than #a year after the date of enactment of this section1 the ,comptroller ,general shall submit to the ,committee on ,energy and ,commerce of the ,house of ,representatives and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate1 a report containing the results of the study under paragraph 7#a74 7h7 ,termination of authority ,the ,secretary may not award a voucher under this section after ,september #cj1 #bjbi4 4 #e4 ,amendment to the ,federal right to try law ,section #efa;,b7b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#j;a7b77 is amended by inserting any provision of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hja et seq47 that prohibits the unauthorized use1 possession1 distribution1 dispensation1 or transportation of an eligible investigational drug1 before and parts4 #f4 ,special registration requirements related to right to try 7a7 ,amendment ,section #cjc of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbc7 is amended by adding at the end the following3 7p7 ,special registration for schedule ,i eligible investigational drugs under right to try 7#a7 ,definitions ,in this subsection1 the terms eligible investigational drug and eligible patient have the meanings given those terms in section #efa;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#j;a74 7#b7 ,special registration process ,the ,attorney ,general shall register physicians to directly administer eligible investigational drugs in schedule ,i to eligible patients under section #efa;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#j;a7 in accordance with paragraphs 7#c7 through 7#f7 of this subsection4 7#c7 ,requirements 7,a7 ,application ,a physician desiring a registration to directly administer an eligible investigational drug as described in paragraph 7#b7 shall submit to the ,attorney ,general an application containing-- 7i7 evidence of a valid registration to dispense or administer controlled substances in schedules ,,ii through ,v2 7ii7 evidence of compliance with section #efa;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#j;a71 including-- 7,i7 documentation from the manufacturer or sponsor verifying the investigational drug in schedule ,i is an eligible investigational drug2 7,,ii7 an agreement from the manufacturer or sponsor to supply the eligible investigational drug1 along with guidance on its administration1 to the requesting physician for the treatment of eligible patients2 and 7,,iii7 an affirmation that the physician will only directly administer the eligible investigational drug to treat eligible patients in a manner consistent with the guidance provided by the manufacturer or sponsor2 7iii7 the quantity of the eligible investigational drug to be supplied by the manufacturer or sponsor to the physician to treat eligible patients2 7iv7 evidence that the physician is allowed to treat patients under the laws of the ,state in which the treatment will take place2 7v7 a description of the site at which the physician intends to store and administer the eligible investigational drug2 and 7vi7 any additional information the ,attorney ,general determines necessary to prevent diversion4 7,b7 ,approval ,not later than #de days after receiving an application containing the information required under subparagraph 7,a71 the ,attorney ,general shall-- 7i7 register the applicant2 or 7ii7 serve an order to show cause upon the applicant in accordance with section #cjd7;c74 7#d7 ,electronic submissions ,the ,attorney ,general shall provide a means for a physician to submit an application under paragraph 7#c77;,a7 electronically4 7#e7 ,limitation on amounts ,a physician treating eligible patients with an eligible investigational drug in schedule ,i under this subsection may only possess the amounts of the eligible investigational drug identified in-- 7,a7 the application submitted to the ,attorney ,general under paragraph 7#c77;,a72 or 7,b7 a supplemental notification that the physician may submit to the ,attorney ,general if the physician needs additional amounts of the eligible investigational drug for the treatment of eligible patients1 which supplemental notification-- 7i7 shall include-- 7,i7 the name of the physician2 7,,ii7 the additional quantity of the eligible investigational drug needed2 and 7,,iii7 an attestation that the treatment with the eligible investigational drug is consistent with the scope of treatment that was the subject of the application under paragraph 7#c77;,a72 and 7ii7 shall be deemed approved on the date that is #cj days after the date on which the physician submits the supplemental notification to the ,attorney ,general1 unless the ,attorney ,general serves an order to show cause upon the applicant in accordance with section #cjd7;c74 7#f7 ,single registration for related treatment sites ,a physician may treat eligible patients with an eligible investigational drug in schedule ,i under a single registration under this subsection if-- 7,a7 the treatment occurs exclusively on sites all of which are-- 7i7 within the same city or county2 and 7ii7 under the control of the same institution1 organization1 or agency2 and 7,b7 before commencing the treatment1 the physician notifies the ,attorney ,general of each site where the eligible investigational drug will be stored or administered in accordance with paragraph 7#c77;,a77vi74 4 7b7 ,rulemaking ,notwithstanding the requirements of section #eec of title #e1 ,united ,states ,code1 not later than #bdj days after the date of enactment of this ,act1 the ,attorney ,general shall issue an interim final rule to implement subsection 7p7 7as added by this section7 of section #cjc of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbc71 including with respect to-- 7#a7 the manner in which an eligible investigational drug may be delivered to an approved registrant2 7#b7 the storage and security of an eligible investigational drug2 7#c7 the maintenance of records for an approved registrant2 7#d7 the process for renewal1 suspension1 or revocation of a registration2 and 7#e7 any other matters necessary to ensure effective controls against diversion4 7c7 ,final rule ,not later than #b years after issuing an interim final rule under subsection 7b71 the ,attorney ,general shall issue a final rule to implement subsection 7p7 7as added by this section7 of section #cjc of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbc7 in accordance with section #eec of title #e1 ,united ,states ,code4 #g4 ,revising considerations for ,,dea quota requirements 7a7 ,in general ,section #cjf of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbf7 is amended-- 7#a7 in subsection 7a7-- 7,a7 in paragraph 7#a7-- 7i7 by striking total2 7ii7 by inserting clinical1 after research12 and 7iii7 by inserting and paragraph 7#c7 after 7#b72 7,b7 in paragraph 7#b71 by inserting 1 in consultation with the ,secretary of ,health and ,human ,services1 after if the ,attorney ,general determines2 and 7,c7 by adding at the end the following3 7#c7 ,the ,attorney ,general shall revise the annually established production quotas within #ij days for any basic class of controlled substance in schedule ,i1 and within #fj days for any basic class of controlled substance in schedule ,,ii1 if any of the following triggering events occurs during the calendar year3 7,a7 ,a controlled substance in schedule ,i or ,,ii is transferred or placed into another class of controlled substances in accordance with applicable law4 7,b7 ,a controlled substance in schedule ,i or ,,ii is approved or cleared by the ,food and ,drug ,administration in accordance with the ,federal ,food1 ,drug1 and ,cosmetic ,act4 7,c7 ,a controlled substance in schedule ,i or ,,ii is designated as a breakthrough therapy under section #ejf of such ,act4 7,d7 ,an exemption for investigational use is granted for a drug in schedule ,i or ,,ii investigational use under section #eje7;i7 of such ,act4 7,e7 ,a drug in schedule ,i or ,,ii is approved by the ,food and ,drug ,administration for use in a phase #c clinical trial4 2 7#b7 in subsection 7c71 by adding at the end the following3 ,upon the occurrence of a triggering event listed in subsection 7a77#c7 with respect to a controlled substance1 a registered manufacturer may apply for an expedited mid-year adjustment of the manufacturing quota determined for such manufacturer under this subsection with respect to such controlled substance42 and 7#c7 by adding at the end the following3 7j7 ,the ,attorney ,general shall establish annual sufficiency standards for each established production quota at levels necessary to meet the legitimate medical1 scientific1 research1 clinical1 and industrial needs of the ,united ,states4 4 #h4 ,federal-,state collaboration 7a7 ,in general ,using funds allocated pursuant to subsection 7c71 the ,secretary of ,health and ,human ,services 7in this section referred to as the ,secretary71 acting through the ,director of the ,advanced ,research ,projects ,agency--,health1 the ,director of the ,national ,institutes of ,health1 and the ,assistant ,secretary for ,mental ,health and ,substance ,use1 may partner with ,states1 territories1 and ,indian ,tribes to implement programs to advance research on1 and development of1 psychedelic drugs1 including ibogaine1 for treating serious mental illnesses4 7b7 ,partnerships ,a partnership under subsection 7a7 may include-- 7#a7 the award of ,federal funds2 7#b7 the provision of technical assistance2 and 7#c7 subject to applicable privacy and other law1 sharing data4 #i4 ,interagency collaboration with the private sector 7a7 ,program ,the ,secretary of ,health and ,human ,services 7in this section referred to as the ,secretary71 in collaboration with the ,secretary of ,veterans ,affairs1 shall carry out a program to collaborate with the private sector to increase clinical trial participation1 data sharing1 and real-world evidence generation regarding psychedelic drugs4 7b7 ,prioritizing breakthrough therapies ,in carrying out the program under subsection 7a71 the ,secretary shall prioritize collaboration regarding psychedelic drugs that are designated as a breakthrough therapy under section #ejf7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7;a774 7c7 ,provision of ,,hhs and ,,va data from clinical studies to ,,fda 7#a7 ,interagency agreement ,subject to paragraph 7#b71 the ,secretary of ,health and ,human ,services1 the ,secretary of ,veterans ,affairs1 and the heads of other ,federal departments and agencies1 shall enter into agreements to provide data from federally conducted or supported clinical trials to the ,food and ,drug ,administration to facilitate the timely evaluation and approval or licensure 7as applicable7 of drugs 7including biological products7 under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cea7 or section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cea74 7#b7 ,applicable provisions ,the provision of data under paragraph 7#a7 shall be subject to other applicable law1 including any privacy restrictions under the ,privacy ,act of #aigd 7#e ,u4,s4,c4 #eeb;a7 and the ,health ,insurance ,portability and ,accountability ,act of #aiif 7,public ,law #ajd-aia74 #aj4 ,timely rescheduling 7a7 ,in general ,section #bja of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #haa7 is amended by adding at the end the following3 7k7 7#a7 ,upon successful completion of phase #c clinical trials for a drug in schedule ,i intended to treat a serious mental health disorder1 the ,attorney ,general1 in consultation with the ,secretary of ,health and ,human ,services1 shall initiate and complete proceedings under subsection 7a7 to determine whether to place such drug in another schedule4 7#b7 ,the ,attorney ,general shall complete proceedings under subsection 7a7 for a drug as quickly as practicable4 7#c7 ,in this subsection1 the term phase #c clinical trial means phase #c clinical investigations conducted pursuant to an exemption for investigational use under section #eje7;i7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act or section #cea7;a77#c7 of the ,public ,health ,service ,act4 4 7b7 ,necessary steps for rescheduling determination ,notwithstanding section #bja and subsections 7a7 and 7b7 of section #bjb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #haa1 #hab7 respecting the scheduling of controlled substances1 the ,attorney ,general shall1 by order1 not later than #fj days after the date of enactment of this ,act1 take all necessary steps to determine whether to transfer ibogaine and ibogaine compounds from schedule ,i of such ,act to schedule ,,ii of such ,act4 #aa4 ,designation of senior official for emerging therapeutic interventions within the ,department of ,veterans ,affairs 7a7 ,designation ,not later than #ij days after the date of enactment of this ,act1 the ,under ,secretary for ,health of the ,department of ,veterans ,affairs shall designate a senior official of the ,department to oversee policy1 programs1 and other activities related to emerging therapeutic interventions4 7b7 ,role1 responsibility1 and authority ,the ,under ,secretary for ,health1 in consultation with the ,secretary of ,veterans ,affairs1 shall prescribe the roles1 responsibilities1 and authorities of the official designated under subsection 7a71 including-- 7#a7 assisting the ,secretary of ,veterans ,affairs1 the ,deputy ,secretary of ,veterans ,affairs1 and the ,under ,secretary for ,health with policies1 operations1 programs1 and activities relating to emerging therapeutic interventions2 7#b7 working in coordination with the ,secretary of ,health and ,human ,services1 the ,commissioner of ,food and ,drugs1 the ,secretary of ,defense1 and the ,attorney ,general to improve the efficiency and effectiveness of all activities related to emerging therapeutic interventions within the ,department of ,veterans ,affairs2 and 7#c7 working with ,federal agencies1 ,state and local governments1 and nongovernmental organizations to improve the delivery of1 and access to1 emerging therapeutic interventions4 7c7 ,briefing on designation and implementation ,not later than #ij days after the date of enactment of this ,act1 the ,secretary of ,veterans ,affairs shall provide a briefing to the ,committees on ,veterans' ,affairs of the ,house of ,representatives and ,senate on-- 7#a7 the status of the designation of the official under subsection 7a72 and 7#b7 the implementation of the roles1 responsibilities1 and the authorities of the official under subsection 7b74 #ab4 ,emerging therapeutic interventions at the ,department of ,veterans ,affairs 7a7 ,report 7#a7 ,in general ,not later than #fj days after the date of enactment of this ,act1 and biannually thereafter1 the ,under ,secretary for ,health of the ,department of ,veterans ,affairs shall submit to the ,committees on ,veterans' ,affairs of the ,house of ,representatives and ,senate a report on the activities of the ,department with respect to emerging therapeutic interventions1 including psychedelic-assisted therapies4 7#b7 ,contents ,at a minimum1 each report under paragraph 7#a7 shall1 with respect to emerging therapeutic interventions1 include-- 7,a7 a summary of research activities1 including a list of active and planned clinical trials1 of the ,department relating to emerging therapeutic interventions2 7,b7 an identification of key findings from clinical outcomes and patient-reported outcomes made during clinical trials conducted or supported by the ,department2 7,c7 the number of veterans enrolled in treatment programs and clinical trials related to emerging therapeutic interventions2 7,d7 interagency coordination efforts of the ,department1 including with the ,food and ,drug ,administration1 the ,drug ,enforcement ,agency1 and other relevant government agencies2 7,e7 recommendations to improve the delivery of innovative therapies to veterans1 including psychedelic-assisted therapies2 and 7,f7 recommendations for legislative or administrative actions relating to emerging therapeutic interventions4 7b7 ,workforce readiness ,the ,under ,secretary for ,health of the ,department of ,veterans ,affairs shall develop a workforce implementation-readiness plan for emerging therapeutic interventions 7including psychedelic-assisted therapies71 including-- 7#a7 conducting a workforce-readiness assessment to identify clinicians and peer support specialists with prior training or certification relevant to emerging therapeutic interventions and gaps in training1 supervision1 and clinical capacity necessary to support safe and effective implementation of such interventions2 7#b7 developing a standardized1 competency-based training framework for clinicians and peer support specialists participating in emerging therapeutic interventions1 including safety monitoring1 supervision standards1 competent care1 interdisciplinary collaboration1 and other areas where appropriate2 and 7#c7 developing and implementing a plan to ensure training1 using such framework1 is conducted1 and credentialing standards are applied1 with respect to the appropriate clinicians and medical centers of the ,department1 including any centers of excellence1 in a manner designed to ensure access across each ,veterans ,integrated ,service ,network4 #ac4 ,report on accelerating medical treatments for serious mental illness 7a7 ,in general ,not later than #ahj days after the date of enactment of this ,act1 the ,secretary of ,veterans ,affairs1 in collaboration with the ,commissioner of ,food and ,drugs and the ,administrator of the ,drug ,enforcement ,agency1 shall provide a report to the appropriate committees of ,congress on the implementation of ,executive ,order #addja 7#ia ,fed4 ,reg4 #bagji1 relating to accelerating medical treatments for serious mental illness74 7b7 ,appropriate committees of ,congress ,in this section1 the term appropriate committees of ,congress means-- 7#a7 the ,committee on ,energy and ,commerce of the ,house of ,representatives2 7#b7 the ,committee on ,veterans' ,affairs of the ,house of ,representatives2 7#c7 the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate2 and 7#d7 the ,committee on ,veterans' ,affairs of the ,senate4